Tirzepatide has become the GLP-1 medication many people ask about first, and for good reason. Here are five things worth knowing before you start.
1. It works on two hormones, not one
Most GLP-1 medications act on a single hormone pathway, GLP-1. Tirzepatide also acts on GIP, a second gut hormone involved in appetite and metabolism. Together they help you feel full sooner, stay full longer and eat less without fighting constant hunger.
2. It led to more weight loss than semaglutide, head to head
In SURMOUNT-5, published in the New England Journal of Medicine in 2025, adults taking tirzepatide lost an average of 20.2% of their body weight over 72 weeks, compared with 13.7% on semaglutide. Nearly half of the tirzepatide group lost 20% or more.
Important: SURMOUNT-5 studied specific FDA-approved tirzepatide and semaglutide regimens. Compounded versions were not studied in SURMOUNT-5 and are not FDA approved.
Read the full breakdown in tirzepatide or semaglutide: how to choose.
3. Results held up over three years
In the three-year SURMOUNT-1 study of adults with prediabetes, weight loss held at about 12% to 20% depending on dose at 176 weeks. Only 1.3% of people taking tirzepatide were diagnosed with type 2 diabetes during treatment, compared with 13.3% on placebo.
4. The FDA-approved version treats more than weight
Tirzepatide was first approved for type 2 diabetes, then for chronic weight management. In December 2024, the FDA approved it as the first medication for moderate to severe obstructive sleep apnea in adults with obesity. These approvals apply to the FDA-approved product; compounded tirzepatide is not FDA-approved.
5. Side effects are usually manageable
The most common side effects are nausea, diarrhea, constipation and reflux, mostly in the first weeks and after a dose increase. Starting at a low dose, eating smaller meals and staying hydrated help most people.
Tirzepatide is also one of the GLP-1 drugs whose labels must now warn about NAION, a rare cause of sudden vision loss in one eye, under the FDA’s November 2026 safety warning on GLP-1s.
Not for use during pregnancy, or for anyone with a personal or family history of medullary thyroid cancer or MEN 2. A clinician reviews your full health history first.
This article is general education, not medical advice. Prescription required. A licensed clinician decides whether treatment is right for you. Compounded tirzepatide and semaglutide are prepared by licensed U.S. pharmacies and are not FDA-approved. Individual results vary.



